Astellas announced that the FDA has designated isavuconazole as a Qualified Infectious Disease Product (QDIP) for the treatment of invasive candidiasis. Isavuconazole is an investigational once-daily ...
Astellas Pharma announced that the FDA has designated isavuconazole a Qualified Infectious Disease Product (QDIP) for the treatment of invasive aspergillosis. Isavuconazole is an investigational ...